To test whether average long-term glucose exposure is associated with cognitive and physical function in middle-aged and younger-old adults with type 2 diabetes mellitus. State Examination) and physical function (Short Physical Performance Battery, expanded Physical Performance Battery, 400-m and 20-m gait speed) and strength (grip and knee extensor strength) were assessed at the Year 8 or 9 follow-up examination. RESULTS: Average HbA1c exposure was 7.0 AE 1.1% (53 AE 11.6 mmol/mol), with 57% of participants classified as having HbA1c levels of less than 7% (<53 mmol/mol), 27% having levels of 7% to 8% (53-64 mmol/mol), and 16% having levels of greater than 8% (>64 mmol/mol). After adjustment for age, sex, race, education, smoking status, alcohol intake, knee pain, physical fitness, body mass index, diabetes mellitus medication and statin use, ancillary year visit, and study arm and site, higher HbA1c was associated with worse physical but not cognitive function. Further adjustment for prevalent diabetes mellitus-related comorbidities made all associations nonsignificant. Results did not differ when stratified according to participant baseline age (<60 vs ≥ 60). CONCLUSION: Results presented here suggest that, in the absence of diabetes mellitus-related complications, longitudinal glucose exposure is not associated with future cognitive and physical function. Optimal management of diabetes mellitus-related comorbidities may prevent or reduce the burden of disability associated with type 2 diabetes mellitus. J Am Geriatr Soc 65:137-145, 2017.
T he prevalence of diagnosed type 2 diabetes mellitus in the United States has increased sharply over the past 2 decades, 1 with one in four adults aged 65 and older manifesting the condition. 2 Type 2 diabetes mellitus is associated with exacerbation of age-related declines in cognitive 3 and physical 4 function. The odds of experiencing frank dementia 5 or lower extremity disability 6, 7 are at least 1.5 times as high for individuals with type 2 diabetes mellitus as for those without. Such cognitive and physical limitations consistently predict loss of independence 8 and consequent higher healthcare spending. 9, 10 One hypothesis suggests that, in individuals with type 2 diabetes mellitus, glucose dysregulation directly contributes to cognitive and physical impairment, because chronically high glucose is a hallmark of the condition, but data supporting this conjecture are mixed. Some, but not all, 11 cross-sectional studies have found that higher levels of glycosylated hemoglobin (HbA1c) are associated with worse cognitive 12, 13 and physical 7, 14 function in individuals with type 2 diabetes mellitus, although recent prospective studies suggest that poor glycemic control (HbA1c >7%; 53 mmol/mol) may 15, 16 or may not 17 be associated with poor cognitive function but paradoxically good self-reported physical function. 18 Thus, the nature of the relationship between HbA1c and cognitive and physical function is unclear.
To help clarify the association, data from the Look AHEAD trial and Movement and Memory (M&M) ancillary study were used to test the hypothesis that chronically high HbA1c levels are associated with age-related functional impairments in adults with type 2 diabetes mellitus. Using measures of HbA1c over 7 years (baseline to Year 8) and cognitive and physical function assessments collected at the Year 8 or 9 (hereafter referred to as Year 8/9) clinical examination, whether longitudinal HbA1c exposure was associated with several objective cognitive and physical function measures sensitive to age-related decline was examined. Because of the rich characterization of the Look AHEAD cohort, whether the observed associations varied according to age or were independent of diabetes mellitus-related comorbidities (cardiovascular disease (CVD), stroke, retinopathy, renal disease, neuropathy, hypertension, depression) was also examined. It was hypothesized that average HbA1c would be inversely related to follow-up measures of cognitive and physical function, particularly in the oldest members of the cohort, and that clinically manifested diabetes mellitus-related comorbidities would drive this association.
METHODS

Look AHEAD Study Design
The design and methods of the Look AHEAD trial (NCT00017953) have been previously published. 19 Briefly, in 16 study centers in the United States, 5,145 overweight or obese individuals with type 2 diabetes mellitus were randomized to participate in a 4-year intensive lifestyle intervention that promoted weight loss through lower caloric intake and greater physical activity (intervention group) or to receive diabetes mellitus support and education (control group). The goal in the intensive lifestyle intervention arm was to induce a loss of at least 7% of participants' initial weight using dietary modification and to increase physical activity to a minimum of 175 minutes per week. 20 The primary outcome was a composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for angina pectoris during a maximum follow-up of 13.5 years. The primary results have been published; no difference was found in the rate of cardiovascular events between groups. 21 The Look AHEAD M&M ancillary study (NCT01410097) enrolled Look AHEAD participants at four clinical centers to assess cognitive and physical function during the weight maintenance phase of the trial at their Year 8 or 9 clinical examination. Only currently active Look AHEAD participants at the Baton Rouge, Denver, Memphis, and Pittsburgh clinics who provided separate informed consent were eligible to enroll. Local institutional review boards approved the Look AHEAD M&M protocol and consent forms before use. Primary results were published, with modest treatment effects observed for physical, but not cognitive, function endpoints.
22,23
Current Study Sample
The four Look AHEAD M&M clinics enrolled 1,331 participants in the Look AHEAD trial at baseline. When Look AHEAD M&M enrollment started, 30 of the original participants had withdrawn from Look AHEAD, 65 had died, and four had been lost to follow-up, leaving 1,232 participants who attended a Year 8 or 9 visit during the Look AHEAD M&M enrollment period. Of these, 1,092 (89%) consented to enroll in the Look AHEAD M&M ancillary study, of whom 1,081 (Baton Rouge, n = 280; Denver, n = 303; Memphis, n = 220; Pittsburgh, n = 278) were seen at the clinic (n = 979) or assessed over the telephone (n = 102). Data for the function measures presented here are from 879 participants who had at least two measures of HbA1c and all relevant covariate information; 65% of the original Look AHEAD enrollees. Final sample sizes differed according to outcome measure (see sections on Assessment of Cognitive and Physical Function).
Assessment of HbA1c
Blood specimens were collected annually after at least a 12-hour fast and were analyzed by the Central Biochemistry Laboratory (Northwest Lipid Research Laboratories, University of Washington, Seattle, WA) using standardized laboratory procedures for measuring HbA1c. In the Look AHEAD trial, HbA1c was assessed at baseline, annually during Years 1 to 4, and then every other year thereafter. For all analyses, HbA1c exposure was the annual average of at least 24 months; the distribution of annual HbA1c measurements was two (0.23%) participants with three measurements, 11 (1.25%) with five, 68 (7.74%) with six, and 798 (90.78%) with seven.
Assessment of Cognitive Function
Following a standardized protocol, the Look AHEAD M&M study assessed cognitive abilities sensitive to aging during a clinic examination at Year 8/9 of the Look AHEAD trial. According to the protocol, participants' blood glucose was assessed before testing and was required to be greater than 70 mg/dL to proceed with the cognitive assessment. Centrally trained and certified examiners who were masked to intervention assignment validated and administrated all tests. 22 The cognitive tests (and associated domains and sample sizes) included Trail-Making Test Parts A (simple attention) and B 24 (executive function-set shifting) (n = 878), Modified Stroop ColorWord Test 25, 26 (executive function-response inhibition) (n = 860), Digit Symbol-Coding 27 (processing speed and executive function-working memory) (n = 878), Rey Auditory Verbal Learning Test 28 (episodic verbal learning and memory) (n = 879), and the Modified Mini-Mental State Examination 29 (global cognitive functioning) (n = 879).
Assessment of Physical Function
The Look AHEAD M&M study assessed objective measures of physical function using centrally trained and certified staff who were masked to intervention assignment during the Year 8/9 clinic examination of the Look AHEAD trial. 23 According to the protocol, blood glucose was assessed before testing and was required to be greater than 70 mg/dL to proceed with the physical assessment. The Short Physical Performance Battery (SPPB) consisted of three hierarchical standing balance tasks held for 10 seconds each (side-by-side, semi-and full-tandem stands), a usual-pace 4-m walk, and five repeated chair stands. 30 Each performance measure was assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 inability to complete the tests. A summary score from 0 (worst performers) to 12 (best performers) was calculated by summing all test scores (n = 852). An expanded Physical Performance Battery (PPB) was also administered to circumvent the ceiling effect of the SPPB. 31 The expanded PPB increased the standing balance tasks to 30 seconds and added a single leg stand. Scores were continuous and ranged from 0 to 3, with higher scores indicative of better performance (n = 852). Usual walking speeds over 20 m (n = 840) and 400 m (n = 797) were also measured. 32 Grip strength (kg) was measured twice per hand using an isometric hydraulic hand dynamometer (Jamar, Bolingbrook, IL), and the maximum force from two trials for the stronger hand was analyzed (n = 828). Finally, maximum knee extensor muscle strength (pounds; 1-repetition maximum) was assessed on a leg extension machine (n = 641). The right leg was tested unless there was a contraindication (e.g., prior knee surgery).
Potential Risk Factors for Cognitive and Physical Limitations
Certified staff measured all risk factors. Standardized questionnaires were used to collect information on selfreported baseline characteristics (age, sex, race, education, smoking status, alcohol use, knee pain) and medical history. Baseline and incident diabetes mellitus-related comorbidities (noted during follow-up examinations occurring before the Year 8/9 testing session) included CVD (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass graft, carotid endarterectomy, angioplasty of lower extremity artery, aortic aneurysm repair, heart failure, congestive heart failure), stroke; retinopathy, renal disease, neuropathy, hypertension (systolic blood pressure > 140 mmHg and antihypertensive medication use), and depression. (Depressive symptoms were assessed in Year 8 using the Beck Depression Inventory (BDI); total BDI scores range from 0 to 63, with higher scores indicating greater severity.) 33 A maximal graded exercise test was administered at baseline and a submaximal graded exercise test at Years 1 and 4 to estimate cardiorespiratory fitness in metabolic equivalents (METS). 34 Height was measured annually in duplicate using a stadiometer, and body mass was measured using a digital scale throughout the Look AHEAD trial. Body mass index (BMI) was calculated as body mass in kilograms divided by height in meters squared at baseline, and Years 1 and 8. Information on diabetes mellitus medications (e.g., thiazolidinediones, biguanides, insulins, meglitinides, sulfonylureas, alpha-glucans, dipeptidyl peptidase 4 inhibitors) and statin use was collected through selfreport at Year 8. Relevant study-related covariates included ancillary visit year, randomization arm, and study site.
Statistical Analysis
Average HbA1c exposure (%) was calculated using a timeweighted approach based on the amount of time elapsed between measurements from baseline to Year 8. All values between baseline and ancillary date were weighed equally, with changes assumed to occur at the midpoint between measurements. The mean value was calculated after generating a HbA1c value for each day between measurements.
Participants were classified into one of three HbA1c categories (<7% (<53 mmol/mol), 7-8% (53-64 mmol/ mol), >8% (>64 mmol/mol) based on recent American Diabetes Association 35 and American Geriatrics Society recommendations. 36 Group differences were compared using the chi-square test for proportions and analysis of variance for continuous variables. Multiple linear regression models were used to assess associations between average HbA1c exposure over 7 years of follow-up and cognitive and physical function assessments. An initial unadjusted model (Model 1) was followed with two sets of adjusted models (Models 2 and 3) fitted for each outcome measure. The baseline covariates in the first adjusted model (Model 2) were age, sex, race, BMI, education level, smoking status, alcohol intake, knee pain, cardiorespiratory fitness (METS), randomization arm, and study site. Adjustments were also made in Model 2for BMI at Years 1 and 8, cardiorespiratory fitness at Years 1 and 4, diabetes mellitus medication use at Year 8, statin use at Year 8, and visit year of the ancillary study (Year 8 or 9). In Model 3, diabetes mellitus-related comorbidities (CVD, stroke, retinopathy, renal disease, neuropathy, hypertension, depression) and hypoglycemic events were further adjusted for. All presented parameter estimates are standardized to 1 standard deviation of each outcome measure to aid in comparability.
To elucidate the relative effects of HbA1c and diabetes mellitus-related comorbidities on cognitive and physical performance, Model 3 was refit including diabetes mellitus-related comorbidities with and without HbA1c exposure. Last, using the covariates included in Model 2, the interaction between the HbA1c effect and an indicator of age (<60 vs ≥60, determined a priori) was tested for to determine whether the relationship between HbA1c and each outcome was consistent across age groups. All analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC), with significance set at P = .05.
RESULTS
Participant Characteristics
The average age of the study sample (n = 879) at randomization was 58.9 AE 6.8 (56% <60 at baseline), 56.4% were female, and 19.3% were African American. Relevant participant characteristics are shown in Tables 1 and 2 according to average HbA1c exposure level over 7 years of follow-up. Fifty-seven percent of participants were categorized as having low HbA1c levels (<7%, 53 mmol/mol; range 4.7-7.0%, 28-53 mmol/mol), 27% as having moderate levels (7-8%, 53-64 mmol/mol), and 16% as having high levels (>8%(64 mmol/mol; range 8.0-13.8%, 64-127 mmol/mol). The coefficient of variation of HbA1c over time was 10.6%, with higher levels of HbA1c associated with higher variability.
Younger age and African-American race were associated with higher average HbA1c exposure (both P < .01). High HbA1c was also associated with higher BMI (Years 1 and 8), Year 8 BDI score, retinopathy, renal disease, hypertension, and diabetes mellitus medication use (all P ≤ .01). For HbA1c exposure categories, there were no pairwise differences in education, smoking status, alcohol intake, knee pain, CVD, stroke, neuropathy, cardiorespiratory fitness, baseline BMI, statin use, ancillary visit year, randomization arm, or study site. Although baseline cognitive and physical function were not assessed, unadjusted performance on the battery of functional tests performed at the Year 8/9 visit, stratified according to average HbA1c, are presented in Table 3 for descriptive purposes. No differences in any of the functional outcome measures were observed across HbA1c categories, although a trend was observed for the Modified Stroop Color-Word Test (P = .05).
Associations Between Cognitive and Physical Function According to Average HbA1c
Model parameter estimates and 95% confidence intervals between performance on cognitive and physical function tests at the Year 8/9 visit and average HbA1c exposure over 7 years of follow-up are presented in Table 4 . In separate unadjusted models, HbA1c was not associated with performance on any outcome measures at the Year 8/9 visit (Model 1). After adjusting for age, sex, race, education, smoking status, alcohol intake, knee pain, METS, BMI, diabetes mellitus medication and statin use, ancillary year visit, study arm, and site (Model 2), parameter estimates between HbA1c and cognitive function were unchanged, although average HbA1c exposure was more consistently associated with physical function in Model 2, with higher average HbA1c exposure associated with lower SPPB and expanded PPB scores and slower 400-and 20-m gait speed (all P ≤ .05). Of covariates included in Model 2, age appeared to have the greatest effect on physical function results and was inversely correlated with HbA1c. 28 (6) 15 (6) 3 (2) Knee pain, n (%)
234 (47) 95 (40) 53 (37) .06
Further adjustment for the presence of diabetes mellitus-related comorbidities attenuated previously significant associations by 54% to 60%, such that they were no longer significant (Model 3). Addition of an indicator variable for hypoglycemic events occurring before the functional assessment visit (n = 35) did not alter these results. Conversely, parameter estimates for diabetes mellitus-related comorbidity effects, which were significantly and inversely related to several functional outcome measures, did not materially change with the addition of HbA1c exposure level (Table S1 ). Lastly, exploratory analyses testing an interaction between age and HbA1c yielded largely nonsignificant results, with the exception of the Modified Stroop Color-Word Test (P for interaction = .03).
DISCUSSION
Despite the interest in high glucose as a pro-aging factor, in this sample of middle-aged and younger-old adults with type 2 diabetes mellitus, average HbA1c over 7 years of follow-up was not associated with cognitive function and was only modestly associated with physical function. Moreover, the inverse relationship between HbA1c and physical function was not apparent after accounting for diabetes mellitus-related comorbidities. This suggests that, in the absence of diabetes mellitus-related complications, HbA1c does not contribute to the development of cognitive and physical dysfunction, although given the inherent limitations of the study design (lack of baseline outcome measures, potential selection bias), findings should be interpreted cautiously and warrant replication using concurrent longitudinal HbA1c and function data. In the past several years, numerous studies have demonstrated that type 2 diabetes mellitus is a risk factor for cognitive and physical decline. It has been speculated that multiple pathophysiological processes underlie this association, including glucose dysregulation and microvascular complications and related comorbidities. 4, 7, 37 One hypothesis linking glucose dysregulation to greater risk of agerelated cognitive and physical impairment posits that chronically high glucose accelerates the accumulation of advanced glycation end products (AGEs), promoting reactions that denature proteins and thereby increase oxidative stress and inflammatory burden. 38 In support of this conjecture, positive associations between AGEs and advanced dementia 39 and between AGEs and poor physical function 40 have been reported.
Although the AGEs hypothesis may be true, and some data implicate high HbA1c in functional decline, 15, 16 overall results from the current study do not support an independent role of high HbA1c in poorer performance on objective measures of cognitive function. This finding is echoed longitudinally in the Atherosclerosis Risk in Communities study, 17 as well as in the Action to Control Cardiovascular Risk in Diabetes-Memory Study, 41 in which randomization to intensive glycemic control (HbA1c <6%, 42 mmol/mol) in participants with type 2 diabetes mellitus did not improve cognitive function.
Alternatively, the current findings suggest that common medical complications of type 2 diabetes mellitus, rather than glucose dysregulation itself, may be responsible for the association between type 2 diabetes mellitus and poorer performance on objective tests of physical function. Type 2 diabetes mellitus-related comorbidities are independent predictors of long-term disability and may contribute to disability through limited cardiopulmonary reserve, restricted physical movement and exercise intolerance, or inflammatory processes. The current findings are data suggesting a greater role for comorbidities than for poor glycemic control in explaining the association between type 2 diabetes mellitus and functional disability. 7 Although a differential effect of HbA1c on function was not observed according to age strata, these analyses were exploratory in nature and specific to relatively "younger" older adults (with more than half of the study sample younger than 60 at baseline). More longitudinal and randomized controlled trial data are necessary to clarify the complex role of glucose regulation in predicting physical function in older populations, especially when considering provocative findings from the On Lok Lifeways Study, in which HbA1c levels of 8.0% to 8.9% (64-74 mmol/mol) independently predicted better functional outcomes in nursing home-eligible older (80 AE 9) adults. 18 The primary limitation of the current study design is the measurement of cognitive and physical function at a single time point. Additionally, despite the well-characterized nature of the Look AHEAD cohort, findings are limited to a study population of adults with type 2 diabetes mellitus who are perhaps too healthy (limited range of HbA1c measures, volunteer selection bias, able to complete a maximal graded exercise test at baseline) and too young to see significant variability in follow-up cognitive and physical function measures. Thus, the results cannot exclude the possibility that HbA1c is an important independent predictor of functional decline at older ages, over a longer follow-up period, and at significantly higher or lower HbA1c levels. Several outcome measures were assessed as part of the cognitive and physical function batteries and may have inflated the Type 1 error rate, but because outcome measures are not independent of one another and analyses were post hoc and largely exploratory, multiple comparisons were not adjusted for. Last, although intervention arm assignment was adjusted for, one inherent limitation of conducting a descriptive study of a randomized controlled trial is the potential for confounding, especially considering legacy effects of the treatment on outcome measures. Strengths include the administration of multiple objective well-validated tests associated with age-related cognitive and physical function decline and a relatively large sample.
In conclusion, results from this study do not support the hypothesis that glucose dysregulation, per se, leads to impairments in cognitive and physical function in overweight and obese adults diagnosed with type 2 diabetes mellitus. Rather, it may hasten the onset of diabetes mellitus-related comorbidities, which in turn are associated with poorer function. Thus, optimal management of diabetes mellitus-related comorbidities may prevent or reduce the burden of physical disability associated with type 2 diabetes mellitus, especially in "younger" older adults, who may be more responsive to intervention; more data are necessary to clarify best practice strategies for preventing or slowing functional decline in the oldest adults with type 2 diabetes mellitus.
